Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024)

Corbus Pharmaceuticals Holdings has reported Total Non-Current Liabilities over the past 6 years, most recently at $35.1 million for Q4 2023.

  • For Q4 2023, Total Non-Current Liabilities rose 5.51% year-over-year to $35.1 million; the TTM value through Dec 2023 reached $35.1 million, up 5.51%, while the annual FY2023 figure was $35.1 million, 5.51% up from the prior year.
  • Total Non-Current Liabilities for Q4 2023 was $35.1 million at Corbus Pharmaceuticals Holdings, down from $35.9 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $57.0 million in Q4 2020 and troughed at $31.9 million in Q3 2022.
  • A 4-year average of $38.3 million and a median of $35.1 million in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 32.3% in 2021 and later rose 12.76% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $57.0 million in 2020, then tumbled by 32.3% to $38.6 million in 2021, then fell by 13.73% to $33.3 million in 2022, then increased by 5.51% to $35.1 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for CRBP at $35.1 million in Q4 2023, $35.9 million in Q3 2023, and $34.2 million in Q2 2023.